BC Innovations | Feb 28, 2019
Distillery Therapeutics

Neurology; inflammation

INDICATION: Stroke; shock/trauma Patient and mouse studies suggest inhibiting CCR5 could help treat stroke and traumatic brain injury (TBI). In stroke patients, the absence of a loss-of-function mutant CCR5 allele was associated with the severity...
BC Extra | Feb 21, 2019
Preclinical News

Repurposing an HIV target could aid brain injury recovery

Extending CCR5 inhibition beyond treating HIV/AIDS, UCLA researchers showed that blocking CCR5 could promote recovery from stroke and traumatic brain injury (TBI). CC chemokine receptor 5 (CCR5; CD195) is well known for its role in...
BC Innovations | Oct 3, 2018
Distillery Therapeutics

Infectious

INDICATION: HIV/AIDS In vitro and cell culture studies identified a heteroarylpropanediamine-based CCR5 antagonist that could help treat HIV-1 infection. Chemical synthesis and in vitro testing in enzymatic activity assays of a series of 1-heteroaryl-1,3-propanediamine analogs...
BC Innovations | Jan 8, 2018
Distillery Therapeutics

Musculoskeletal

INDICATION: Osteoporosis Mouse studies suggest CCR5 inhibitors could help treat osteoporosis. In a mouse model of osteoporosis, systemic knockout of CCR5 decreased trabecular bone loss in the femur compared with normal expression. Next steps could...
BC Innovations | Nov 28, 2017
Distillery Therapeutics

Cancer

INDICATION: Melanoma Patient sample and mouse studies suggest inhibiting CCR5 or its interactions with CCL3, CCL4 and RANTES could help treat melanoma. In patient tissue samples, the number of CCR5-positive myeloid-derived suppressor cells (MDSC) and...
BC Innovations | May 4, 2017
Translation in Brief

Tethered hope

A Scripps team has developed a method for identifying antiviral, membrane-tethered antibodies that block virus-host receptor interactions without disrupting normal receptor functions, a strategy that could both reduce the ability of the virus to develop...
BC Innovations | Nov 19, 2015
Distillery Therapeutics

Therapeutics: μ opioid receptor (MOR; OPRM1); CC chemokine receptor 5 (CCR5; CD195)

Neurology INDICATION: Pain In vitro and mouse studies suggest a conjugate of an MOR agonist and a CCR5 antagonist could help treat inflammation-associated pain. The conjugate consisted of the generic MOR agonist oxymorphone and a...
BC Innovations | Jan 8, 2015
Distillery Therapeutics

Therapeutics: CC chemokine receptor 5 (CCR5; CD195)

Cancer INDICATION: Prostate cancer Mouse studies suggest CCR5 antagonists could help prevent prostate cancer metastasis. In mouse models of metastatic prostate cancer, the CCR5 antagonist Selzentry maraviroc decreased metastatic burden by 80% in bone and...
BC Week In Review | Sep 1, 2014
Clinical News

Selzentry: Phase III data

The 96-week, double-blind, double-dummy, international Phase III MODERN trial in 797 antiretroviral-naive patients with CCR5-tropic HIV-1 infection showed that once-daily 150 mg maraviroc plus darunavir/ritonavir missed the primary endpoint of non-inferiority to once-daily Truvada emtricitabine/tenofovir...
BC Innovations | Oct 10, 2013
Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Crystal structure of Selzentry maraviroc-bound HIV-1 co-receptor CC chemokine receptor 5 (CCR5; CD195) The crystal structure of HIV-1 co-receptor CCR5 bound by the allosteric inhibitor...
Items per page:
1 - 10 of 105